Key Preclinical Data Highlights SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic ...

SIL-204 reduced tumor growth by ~50% and caused complete necrosis in ~50% of human pancreatic tumors in mice models with G12D mutations. A single systemic dose of SIL-204 sustained effective drug ...

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...